12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BenzingaJan 22 07:05 ET

Contineum Therapeutics Analyst Ratings

BenzingaJan 9 10:19 ET · Ratings

RBC Capital Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $31

Moomoo NewsJan 9 07:31 ET · Ratings

Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy From RBC Capital

TipRanksJan 9 06:55 ET · Ratings

Contineum Therapeutics Completes Enrollment In Phase 2 PIPE-307 VISTA Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis; The Last Patient Is Expected To Complete The Trial In Q3 2025

BenzingaJan 8 16:08 ET

Express News | Contineum Therapeutics Completes Enrollment in Phase 2 Pipe-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (Rrms)

ReutersJan 8 16:05 ET